All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Mosunetuzumab monotherapy in patients with R/R FL after ≥2 prior lines of therapies: 3-year follow-up results from the phase II trial
Bookmark this article
|
A phase II trial (NCT02500407) assessed the safety and efficacy of mosunetuzumab, a CD20×CD3 T-cell-engaging bispecific antibody, in patients with R/R FL after ≥2 prior lines of therapy.1 Based on results from this trial, mosunetuzumab was approved by the FDA and the European Commission for the treatment of patients with R/R FL after ≥2 prior lines of therapy. The 3-year follow-up results of this trial were presented at the SOHO 2024 Annual Meeting by Schuster.1 The data cut-off was May 2, 2023, and study endpoints were PFS, OS, DoR, safety, and uMRD.1 |
| Key learnings |
| With a median follow-up of >3 years, mosunetuzumab achieved long-lasting remissions, with 3-year PFS and OS rates of 43.2% and 82.4%, respectively. The median DOR was 35.9 months and the 30-month DOR rate was 56.6%. |
| No new safety signals were reported during this long-term follow-up. The most common AEs and mosunetuzumab-related AEs with an incidence of ≥15% were CRS (44%; all resolved), fatigue, and headache; these were mostly Grade 1 or 2. |
| MRD analysis showed early deep molecular responses. Among patients achieving CR, uMRD was attained at C4 and C8 in 93% and 100% of patients, respectively. |
| Exploratory analysis showed detectable B-cell recovery at a median time of 18.4 months after the end of treatment. |
| Data from the pivotal phase II trial demonstrate the durable clinical efficacy and tolerable safety of mosunetuzumab monotherapy, supporting its use in patients with R/R FL after ≥2 prior lines of therapy. |
Abbreviations: AE, adverse event; C, cycle; CR, complete response; DoR, duration of response; FDA, U.S. Food and Drug Administration; FL, follicular lymphoma; MRD, minimal residual disease; OS, overall survival; PFS, progression-free survival; R/R, relapsed and refractory; SOHO, Society of Hematologic Oncology; uMRD, undetectable MRD.
- Schuster SJ. Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal phase II study. Poster #IBCL-335. Presented at: Society of Hematologic Oncology 2024 Annual Meeting; Sep 4–7, 2024; Houston, US.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
41 votes - 80 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox